Holen Sie sich die Stockscreener-App
4.45
2.41%
-0.11
Schlusskurs vom Vortag:
$4.56
Offen:
$4.55
24-Stunden-Volumen:
9.00M
Relative Volume:
2.04
Marktkapitalisierung:
$881.57M
Einnahmen:
$191.45M
Nettoeinkommen (Verlust:
$160.72M
KGV:
5.4103
EPS:
0.8225
Netto-Cashflow:
$-34.44M
1W Leistung:
-8.25%
1M Leistung:
-12.75%
6M Leistung:
-0.67%
1J Leistung:
-0.89%
1-Tages-Spanne:
$4.375
$4.68
1-Wochen-Bereich:
$4.375
$4.95
52-Wochen-Spanne:
$3.50
$5.45
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.45 | 960.81M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
Arbutus Biopharma (ABUS) Shares Rise on $230M Share Buyback Comp - GuruFocus
An up-to-$230M share offer expired; Arbutus Biopharma (ABUS) announced preliminary results. - Stock Titan
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire
About 23% of Arbutus shares are being bought back for $230 million. - Stock Titan
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com - Investing.com Nigeria
ABUS Stock Price, Quote & Chart - ChartMill
Arbutus Biopharma Corp (ABUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS) - stocktitan.net
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arbutus Biopharma Corp (ABUS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Cronos Group Inc. Common Share (CRON) Peer Comparison – Compare with Others - Value Research
Acasti Pharma Inc. Class AADR Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Fed. Circ. Agrees To Speed Up Args In COVID Vax Patent Case - Law360
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Arbutus Biopharma Announces $230 Million Modified Dutch Auction Tender Offer for Shares - Kalkine Media
Why is Arbutus Biopharma stock surging today? - Investing.com India
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified 'Dutch Auction” Tender Offer - The Manila Times
Arbutus Biopharma Corporation authorizes a Buyback Plan. - marketscreener.com
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Moderna Vaccine Appeal Poised to Set Patent Liability Benchmark - Bloomberg Law News
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - Stock Titan
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma earnings matched, revenue topped estimates - Investing.com
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact - Kalkine Media
ABUS Looks 90.7% Undervalued on GF Value™ Despite Revenue Challe - GuruFocus
What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings - GuruFocus
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com - Investing.com Nigeria
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary - TradingView
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arbutus Biopharma Corp-Aktie (ABUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nguyen Tuan | Chief Financial Officer |
Sep 18 '26 |
Option Exercise |
3.57 |
293,100 |
1,047,646 |
366,600 |
| Sawhney Roger | Director |
Sep 18 '26 |
Option Exercise |
3.88 |
131,333 |
509,572 |
131,333 |
| Beardsley Robert A | Director |
Sep 18 '26 |
Option Exercise |
3.82 |
131,333 |
502,218 |
131,333 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):